The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Challenges in Disproportionality Analysis: Understanding Their Intricate Nature and Proposing an Initial Mitigation Approach

  • By

  • Manfred Hauben

  • Rave Harpaz

  • Robert Weber

  • September 17, 2026

Share

  • 1

    Disproportionality analysis (DPA) practitioners face fundamental pitfalls, particularly confounding by demographic variables.

  • 2

    The regression-adjusted gamma-Poisson shrinker (RGPS) enhances DPA by adjusting for co-reported products and covariates.

  • 3

    RGPS identifies masking effects, where true drug-event associations may be concealed by other products increasing background reporting rates.

  • 4

    Standardized regression coefficients (SRCs) from RGPS help assess the independent contributions of drugs and covariates to expected counts.

  • 5

    The interplay of confounding and masking can significantly affect the interpretation of drug-event associations in pharmacovigilance.

Original Source(s)

The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy

  • by Manfred Hauben, Rave Harpaz, Robert Weber

  • September 17, 2026

Related Content

Germline Multigene Panel Testing in Women With Invasive Lobular Cancer

Implementation Strategies in Cascade Genetic Testing—The Devil Is in the Details

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

  • 1 min